Selcuk Ecza Deposu Ticaret ve Sanayi AS
IST:SELEC.E
Gross Margin
Selcuk Ecza Deposu Ticaret ve Sanayi AS
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| TR |
|
Selcuk Ecza Deposu Ticaret ve Sanayi AS
IST:SELEC.E
|
39.1B TRY |
10%
|
|
| US |
|
Mckesson Corp
NYSE:MCK
|
85.6B USD |
4%
|
|
| US |
|
Cencora Inc
NYSE:COR
|
54.1B USD |
3%
|
|
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
53.2B USD |
3%
|
|
| US |
|
Cardinal Health Inc
NYSE:CAH
|
31.2B USD |
3%
|
|
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
34.6B AUD |
9%
|
|
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
64.6B CNY |
32%
|
|
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW |
30%
|
|
| AU |
E
|
EBOS Group Ltd
OTC:EBOSY
|
8.2B USD |
13%
|
|
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
7.9B USD |
32%
|
|
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
53.3B CNY |
11%
|
Selcuk Ecza Deposu Ticaret ve Sanayi AS
Glance View
In the dynamic landscape of Turkey's pharmaceutical industry, Selçuk Ecza Deposu Ticaret ve Sanayi A.Ş. stands as a formidable force, deftly operating as a bridge between pharmaceutical manufacturers and healthcare providers. Established in 1958, the company has cultivated an extensive distribution network that covers the length and breadth of Turkey. With a meticulously coordinated logistics framework, Selçuk Ecza ensures that a vast array of pharmaceutical products—from essential medicines to specialized healthcare solutions—reach pharmacies, hospitals, and healthcare institutions efficiently. This seamless operation is buoyed by the company’s ability to adapt to the ever-changing regulatory environment and consumer demands, thereby ensuring its relevance in the market for decades. The essence of Selçuk Ecza’s business model lies in its comprehensive approach to distribution, where it capitalizes on economies of scale to ensure cost-effectiveness while maintaining high-quality service standards. Revenue is generated primarily through the sales margins on the wide range of pharmaceuticals it distributes. The company’s proficiency in maintaining robust relationships with global pharmaceutical giants and local suppliers alike underpins its substantial market share. Furthermore, by embracing technological advancements, such as real-time inventory management systems, Selçuk Ecza optimizes its supply chain operations, minimizing delays and maximizing efficiency. This strategic prowess not only cements its position as a leading distributor in Turkey but also fosters sustainable growth by continuously aligning with the dynamic healthcare industry.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Selcuk Ecza Deposu Ticaret ve Sanayi AS's most recent financial statements, the company has Gross Margin of 10.1%.
You don't have any saved screeners yet